Tania Kuempfel

Summary

Affiliation: University of Munich
Country: Germany

Publications

  1. doi request reprint Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)
    Corinna Trebst
    Department of Neurology, Hannover Medical School, Hannover, Germany
    J Neurol 261:1-16. 2014
  2. doi request reprint Familial Mediterranean fever-associated mutation pyrin E148Q as a potential risk factor for multiple sclerosis
    T Kümpfel
    Institute of Clinical Neuroimmunology Großhadern, Ludwig Maximilians University of Munich, Germany
    Mult Scler 18:1229-38. 2012
  3. pmc Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients
    Sven Jarius
    Neurocure, Charite University Medicine Berlin, Berlin, Germany
    J Neuroinflammation 9:14. 2012
  4. doi request reprint Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment
    Joachim B Havla
    Institute of Clinical Neuroimmunology, Ludwig Maximilians University, Marchioninistr 15, 81377 Munich, Germany
    Arch Neurol 69:262-4. 2012
  5. pmc Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations
    Florian Then Bergh
    Section of Neurology, Max Planck Institut fur Psychiatrie, Munchen, Germany
    BMC Neurol 6:19. 2006
  6. doi request reprint Multiple sclerosis. TNFRSF1A, TRAPS and multiple sclerosis
    Tania Kümpfel
    Institute of Clinical Neuroimmunology Campus Grosshadern, Ludwig Maximilians University of Munich, Marchioninistrasse 15, Munich, Germany
    Nat Rev Neurol 5:528-9. 2009
  7. doi request reprint Multiple sclerosis and the TNFRSF1A R92Q mutation: clinical characteristics of 21 cases
    T Kümpfel
    Institute of Clinical Neuroimmunology Grosshadern, Ludwig Maximilians University of Munich, Munich, Germany
    Neurology 71:1812-20. 2008
  8. ncbi request reprint Time of interferon-beta 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients
    T Kümpfel
    Institute of Clinical Neuroimmunology, Klinikum Grosshadern, Ludwig Maximilians Universitat, Munich, Germany
    Mult Scler 13:1138-45. 2007
  9. ncbi request reprint Late-onset tumor necrosis factor receptor-associated periodic syndrome in multiple sclerosis patients carrying the TNFRSF1A R92Q mutation
    Tania Kümpfel
    Institute of Clinical Neuroimmunology Grosshadern, Ludwig Maximilian University of Munich, Marchioninistrasse 15, D 81377 Munich, Germany
    Arthritis Rheum 56:2774-83. 2007
  10. doi request reprint De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate
    Joachim Havla
    Institute of Clinical Neuroimmunology, Medical Campus Grosshadern, Ludwig Maximilians University, Marchioninistr 15, 81377 Munich, Germany
    J Neurol 258:1665-9. 2011

Collaborators

  • L A Hoffmann
  • Reinhard Hohlfeld
  • W Pöllmann
  • Markus Krumbholz
  • Florian Holsboer
  • A Blaschek
  • Martin S Weber
  • Birgit Ertl-Wagner
  • F Weber
  • M Uhr
  • Ralf Gold
  • Klaus Dornmair
  • Hartmut Wekerle
  • Raymond Voltz
  • Bernhard Hemmer
  • C Trenkwalder
  • Hannah Pellkofer
  • P Flachenecker
  • Tania Kümpfel
  • T Kümpfel
  • Corinna Trebst
  • Sven Jarius
  • Achim Berthele
  • Florian Then Bergh
  • Brigitte Wildemann
  • Sven Schippling
  • Orhan Aktas
  • Friedemann Paul
  • Ingo Kleiter
  • Michael Ingrisch
  • Joachim B Havla
  • Ingrid Meinl
  • Lisa Ann Gerdes
  • Joachim Havla
  • Klaus Lehmann-Horn
  • P Lohse
  • W Feneberg
  • Birgit Obermeier
  • Michaela Gottschalk
  • Dorothee P Auer
  • Erina M Schumann
  • Nadja Borisow
  • Martin Liebetrau
  • Uwe K Zettl U
  • Christian Wilke
  • Steven Sourbron
  • Christian Glaser
  • Peter Kern
  • Sabine Niehaus
  • Tobias Boettcher
  • T Wacker
  • Dominik Morhard
  • Imke Metz
  • Johannes Brettschneider
  • Klaus P Wandinger
  • Stefan Langel
  • Hayrettin Tumani
  • Florian Lauda
  • Christoph Munch
  • Christoph A Mayer
  • Christian Veauthier
  • Barbara Ettrich
  • Martin Marziniak
  • Alexander Winkelmann
  • Ulf Ziemann
  • Marius Ringelstein
  • Reinhard Reuss
  • Hans P Hartung
  • Jürgen H Faiss
  • Christian Zentner
  • Frank Hoffmann
  • Kerstin Hellwig
  • Martin Stangel
  • L A Gerdes
  • J Havla
  • Klemens Ruprecht
  • Ralf A Linker
  • Christoph Kleinschnitz
  • Paulus S Rommer
  • Maximilian Reiser
  • Christian Geis
  • Jörn P Sieb
  • Ulrich Hofstadt-van Oy
  • Kersten Guthke
  • Arthur Melms
  • Oliver Neuhaus
  • Deetje Hertzenberg
  • Nikolas von Bubnoff
  • Alexander Hapfelmeier
  • Hans Faber

Detail Information

Publications17

  1. doi request reprint Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)
    Corinna Trebst
    Department of Neurology, Hannover Medical School, Hannover, Germany
    J Neurol 261:1-16. 2014
    ..Promising new therapies are emerging in the form of anti-IL6 receptor, anti-complement or anti-AQP4-Ab biologicals. ..
  2. doi request reprint Familial Mediterranean fever-associated mutation pyrin E148Q as a potential risk factor for multiple sclerosis
    T Kümpfel
    Institute of Clinical Neuroimmunology Großhadern, Ludwig Maximilians University of Munich, Germany
    Mult Scler 18:1229-38. 2012
    ..A possible association of FMF and multiple sclerosis (MS) has been suggested in cohorts from Turkey and Israel...
  3. pmc Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients
    Sven Jarius
    Neurocure, Charite University Medicine Berlin, Berlin, Germany
    J Neuroinflammation 9:14. 2012
    ..However, little is known so far about the clinical impact of AQP4-Ab seropositivity...
  4. doi request reprint Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment
    Joachim B Havla
    Institute of Clinical Neuroimmunology, Ludwig Maximilians University, Marchioninistr 15, 81377 Munich, Germany
    Arch Neurol 69:262-4. 2012
    ..To date, data about a possible recurrence of disease activity after discontinuation of fingolimod treatment are scarce...
  5. pmc Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations
    Florian Then Bergh
    Section of Neurology, Max Planck Institut fur Psychiatrie, Munchen, Germany
    BMC Neurol 6:19. 2006
    ..Intermittent IV-MP, alone or with immunomodulators, has been suggested but insufficiently studied as a strategy to prevent relapses...
  6. doi request reprint Multiple sclerosis. TNFRSF1A, TRAPS and multiple sclerosis
    Tania Kümpfel
    Institute of Clinical Neuroimmunology Campus Grosshadern, Ludwig Maximilians University of Munich, Marchioninistrasse 15, Munich, Germany
    Nat Rev Neurol 5:528-9. 2009
    ..This locus is of special interest because the R92Q substitution was previously detected in a group of multiple sclerosis patients who had additional symptoms compatible with the autoinflammatory syndrome TRAPS...
  7. doi request reprint Multiple sclerosis and the TNFRSF1A R92Q mutation: clinical characteristics of 21 cases
    T Kümpfel
    Institute of Clinical Neuroimmunology Grosshadern, Ludwig Maximilians University of Munich, Munich, Germany
    Neurology 71:1812-20. 2008
    ..The current study presents the characteristics of a larger cohort of MS patients carrying this mutation...
  8. ncbi request reprint Time of interferon-beta 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients
    T Kümpfel
    Institute of Clinical Neuroimmunology, Klinikum Grosshadern, Ludwig Maximilians Universitat, Munich, Germany
    Mult Scler 13:1138-45. 2007
    ..This may have implications on the tolerability and effectiveness of IFN-beta therapy...
  9. ncbi request reprint Late-onset tumor necrosis factor receptor-associated periodic syndrome in multiple sclerosis patients carrying the TNFRSF1A R92Q mutation
    Tania Kümpfel
    Institute of Clinical Neuroimmunology Grosshadern, Ludwig Maximilian University of Munich, Marchioninistrasse 15, D 81377 Munich, Germany
    Arthritis Rheum 56:2774-83. 2007
    ..We undertook this study to investigate the prevalence of TRAPS in patients with multiple sclerosis (MS) who reported, in addition to their neurologic symptoms, at least 2 other symptoms compatible with TRAPS...
  10. doi request reprint De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate
    Joachim Havla
    Institute of Clinical Neuroimmunology, Medical Campus Grosshadern, Ludwig Maximilians University, Marchioninistr 15, 81377 Munich, Germany
    J Neurol 258:1665-9. 2011
    ..Further treatment strategies are warranted for patients who discontinue NAT therapy...
  11. ncbi request reprint Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies
    Markus Krumbholz
    Institute for Clinical Neuroimmunology, Ludwig Maximilian University, Marchioninistrasse 15, 81377 Munich, Germany
    Arch Neurol 64:1331-3. 2007
    ..In the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) trial, infusion-related hypersensitivity reactions developed in 4% of patients, usually within 2 hours after starting the infusion...
  12. doi request reprint Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction
    Hannah L Pellkofer
    Institute of Clinical Neuroimmunology, Ludwig Maximilians University, Campus Grosshadern, Marchioninistr 15, D 81377 Munich, Germany
    Muscle Nerve 40:305-8. 2009
    ..While conventional immunosuppressive therapy (steroids, azathioprine) failed, he improved with plasma exchange and consecutive treatment with rituximab. Muscle Nerve 40: 305-308, 2009...
  13. pmc Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders
    Klaus Lehmann-Horn
    Department of Neurology, Technische Universitat Munchen, Munich, Germany
    J Neuroinflammation 8:146. 2011
    ..We elucidated the regulatory role of un-activated B-cells in EAE and investigated whether anti-CD20 may collaterally diminish regulatory B-cell properties in treatment of neuroimmunological disorders...
  14. doi request reprint Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis
    Birgit Obermeier
    Institute of Clinical Neuroimmunology, Ludwig Maximilians University, University Hospital Grosshadern, Marchioninistrasse 15, D 81377 Munich, Germany
    Nat Med 14:688-93. 2008
    ..This approach can be applied to other organ-specific diagnostic fluid or tissue samples to compare the Ig transcripts of local B cells with the corresponding antibody proteomes of individual subjects...
  15. doi request reprint Quantification of perfusion and permeability in multiple sclerosis: dynamic contrast-enhanced MRI in 3D at 3T
    Michael Ingrisch
    Josef Lissner Laboratory for Biomedical Imaging, Department of Clinical Radiology, University Hospitals Munich Grosshadern, Ludwig Maximilian University of Munich, Germany
    Invest Radiol 47:252-8. 2012
    ....
  16. ncbi request reprint Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis
    Michaela Gottschalk
    Max Planck Institute of Psychiatry, Munich, Germany
    Arch Neurol 62:277-80. 2005
    ..Fatigue is a common and disabling symptom in patients with multiple sclerosis (MS). Underlying mechanisms postulated so far have involved localization of brain lesions and abnormalities of the neuroendocrine system and cytokine regulation...
  17. ncbi request reprint Activity of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: correlations with gadolinium-enhancing lesions and ventricular volume
    Erina M Schumann
    Max Planck Institute of Psychiatry, Munich, Germany
    Ann Neurol 51:763-7. 2002
    ..In contrast, the nature of the correlation between hypothalamic-pituitary-adrenal hyperdrive and brain atrophy remains to be determined...